



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Editorial Office
✉ research.integrity@frontiersin.org

RECEIVED 07 February 2024
ACCEPTED 09 February 2024
PUBLISHED 20 February 2024

CITATION
Frontiers Editorial Office (2024) Retraction:
The efficacy and adverse effects of anlotinib
in the treatment of high-grade glioma: a
retrospective analysis.
Front. Oncol. 14:1383410.
doi: 10.3389/fonc.2024.1383410

COPYRIGHT
© 2024 Frontiers Editorial Office. This is an
open-access article distributed under the terms
of the [Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Retraction: The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: a retrospective analysis

Frontiers Editorial Office*

A Retraction of the Original Research Article

The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: a retrospective analysis

by Shen F, Li J, Liu F, Sun N, Qiu X, Ding W and Sun X (2023) *Front. Oncol.* 13:1095362.
doi: 10.3389/fonc.2023.1095362

The journal retracts the 2023 article cited above.

Following publication, the publisher identified concerns regarding the scope and peer review of this article. A subsequent investigation, which was conducted in accordance with Frontiers' policies, found indicators of third-party involvement and inadequate peer review process. As the scientific integrity of the article cannot be guaranteed, and adhering to the recommendations of the Committee on Publication Ethics (COPE), the article is retracted.

The authors have not responded to this retraction.

This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers.